From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Cc: s 22(1)(a)(ii)
Subject: FW: Potential Supplier Information sheet [SEC=OFFICIAL]
Date: Wednesday, 15 April 2020 7:51:33 PM
Attachments: image001.png
COVID-19 Potential Supplier Information Sheet - 2 Apr 2020.docx
2020-04-14 - National Medical Stockpile - Procurement Report Draft v7.docx

---

Hi All,
Please find attached the current screening material from the Department of Health for those Companies that have been contracted, or being considered for contract for the supply of PPE Material. You will notice that this maybe reasonable in normal circumstances but falls far short of what we need if we are going to have some confidence in the supply of PPE to those companies who have been contracted to deliver. So, can we do a quick reconciliation between this, and ours, and highlight the difference.
s 22(1)(a)(ii) who is the s 22(1)(a)(ii) responsible for contract sourcing is on the same page as us, in that he can't really check the third parties who may be supplying the contracted entity. Also, please see find the updated Procurement Documentation for those companies that have contracted to source material.
My thinking is that we need to use our screening process documentation, for s 22(1)(a) Ventilators, and baseline all those contracted, or considered for contract. It is the only way we can then start to review the supply chain, and have confidence in the goods being landed.
Thoughts…?

s 22(1)(a)(ii), s 47F

s 22(1)(a)(ii), s 47F @au.ey.com
From: s 22(1)(a)(ii), s 47F
Sent: Wednesday, April 15, 2020 5:05 PM
To: s 22(1)(a)(ii)
Subject: Potential Supplier Information sheet [SEC=OFFICIAL]
As requested

Cheers
☺
s 22(1)(a)(ii), s 47F

Gene Technology Policy Section
Regulatory Policy Branch | Office of Health Protection Division
Australian Government Department of Health
T: s 22(1)(a)(ii) @health.gov.au
GPO Box 9848, Canberra ACT 2601, Australia
The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

COVID-19 Potential Supplier Information Sheet

On 30 January 2020 an outbreak was declared a Public Health Emergency of International Concern. This global alert was issued By the World Health Organization (WHO) in relation to Coronavirus. The Australian Government is procuring equipment and consumables from both Australian and international producers and suppliers.

To expedite the procurement we recommend all potential suppliers provide the information described below. While all supplier offers will be considered, the more detailed information that your business provides will help reduce delays and allow us to better consider your offer. Due diligence is performed on all potential suppliers.

About your business

In order to understand your capabilities to supply the product offered, the following information is helpful (especially for suppliers without a pre-existing relationship with the Department of Health):

- company certification (including certified translation if it is not in English)
- a copy of your most recent audited financial statements
- details of previous experience in supplying products of this type and at the quantity you offer
- referee details of clients who you have previously provided products of this support (if any)
- details of your supply chain and manufacturers
- details of the business entity to be entered on the contract

Product offer and quote

In order for us to evaluate your product offer, provide the following information:

- Product specification (include ARTG numbers, if applicable – see *standards and certification* below)
- Product limitations (this may include whether all parts supplied or if use limited to specific equipment), if applicable
- Quantities that you can supply reliably
- unit prices
- freight costs (including sea/air options if available)
- minimum order requirement, if applicable
- whether you are making an offer to make a one-time supply, or you are offering to supply on a continuing basis
- clearly identify whether the quote includes GST

Delivery

Provide information on:

- Delivery schedule – when will product be available
- delivery and/or storage of supplies including the number of locations in Australia
- special storage requirements (e.g. cold storage) and package dimensions
- how you will confirm acceptance of goods meeting specifications
- distribution of supplies

Terms with downstream manufacturer

If you are contracting another manufacturer to supply you with goods, provide information on:

- Existence of a contract with the manufacturer
- Quality control and audits (batch numbers, production documentation, packing lists, export documentation)
- Your payment terms with the manufacturer

Payment terms

Provide the payment terms that you are considering.

Provide justification for payment terms that have significant pre-payments.

Contracts

Note: Unless and until a written contract is signed by the Department's authorised delegate, no legal obligations or rights exist between us. The Department makes no assurances that it will proceed with your proposal.

The Department would only be able to consider your proposal further, if any deposit or prepayment was secured by an appropriate bank guarantee from an acceptable bank. Alternatively the Department may consider payment on delivery and acceptance of goods in Australia, as a possible approach.

Administration

If you have not had a contract previously with the Department of Health you will be provided a *Vendor form* which allows us to add your business details into our financial system.

Standards and certification

- Consider whether your product must be currently included on the Australian Register of Therapeutic Goods (ARTG) maintained by the Therapeutic Goods Administration and/or meet the current Australian standards as required by the Standards Australia (for example Standards Australia/Standards New Zealand (AS/NZS) 2012, Respiratory protective devices; AS/NZS 1716:2012). If the products meet the standards, then the products are acceptable for supply and for use in public hospital systems across all states and territories in Australia.
- All products certified and approved by the National Institute for Occupational Safety and Health (NIOSH), are acceptable for supply into the National Medical Stockpile, including the supply of N95 Respirators which is equivalent to P2 Respirators (equivalent in requirements and specifications due to Certification and Approval by the EU and European Standards) and Surgical masks that meet the approval and certification by NIOSH.
- Certain products require a Biological Import Permit before they can be imported to Australia. Consider whether you need to obtain a permit (https://www.agriculture.gov.au/import/online-services/bicon).

See the summary table below for minimum specifications we expect for different product categories.

	Specifications
Ventilators	The ventilator system to deliver selectable models of respiratory support or mechanical ventilation to neo-natal, paediatric and adult patients, invasively or non-invasively. The intended use is for in hospitals or during intra-hospital transport. ARTG Number must be supplied.

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Subject: FW: Request for information [DLM=For-Official-Use-Only]
Date: Wednesday, 15 April 2020 1:11:34 PM
Attachments: image001.png
2020-04-14 - National Medical Stockpile - Procurement Report Draft v7.docx

---

Hi All,
This is the latest file on the NMS and contracts executed, contracts in negotiation, and those that are to be offered.
As you can see we finally have the go-ahead to have the discussion with health.
Regards

s 22(1)(a)(ii), s 47F

s 22(1)(a)(ii) @au.ey.com

From: Tan, William
Sent: Wednesday, April 15, 2020 1:03 PM
To: s 22(1)(a)(ii)
Subject: FW: Request for information [DLM=For-Official-Use-Only]

For Official Use Only

From: Haslam, Travis [mailto:s 22(1)(a)(ii) @health.gov.au]
Sent: Tuesday, 14 April 2020 6:45 PM
To: Tan, William <s 22(1)(a)(ii) @industry.gov.au>; s 22(1)(a)(ii) @health.gov.au>
Cc: s 22(1)(a)(ii) @industry.gov.au>; Beauchamp, Glenys <s 22(1)(a)(ii) @industry.gov.au>; s 22(1)(a)(ii) @industry.gov.au>; s 22(1)(a)(ii) @industry.gov.au>; s 22(1)(a)(ii) @health.gov.au>; Luchetti, Narelle <s 22(1)(a)(ii), s 47F @industry.gov.au>
Subject: RE: Request for information [SEC=OFFICIAL:Sensitive]

Hi Will and all,
Attached is the latest contract info as requested. New updates in red. I would be happy to provide this on a weekly basis, with individual emails when a new contract is signed.
I sent the info on S/T data to s 22(1)(a)(ii) separately earlier.
s 22(1)(a)(ii)

In terms of the new reports, I am happy to discuss further as we need to consider how we are meeting shared expectations of Ministers.
Kind regards
Travis

Travis Haslam
Assistant Secretary / National Incident Room

Australian Government Department of Health
T: s 22(1)(a)(ii), s 47F @health.gov.au
s 22(1)(a)(ii)
GPO Box 9848, Canberra ACT 2601, Australia
The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: Tan, William <s 22(1)(a)(ii), s 47F @industry.gov.au>
Sent: Tuesday, 14 April 2020 12:27 PM

To: Haslam, Travis <s 22(1)(a)(ii), s 47F @health.gov.au>; s 22(1)(a)(ii), s 47F @Protected.Health.gov.au>
Cc: s 22(1)(a)(ii) @industry.gov.au>; Beauchamp, Glenys <s 22(1)(a)(ii), s 47F @industry.gov.au>; s 22(1)(a)(ii) @industry.gov.au>; s 22(1)(a)(ii) @industry.gov.au>
Subject: Request for information [DLM=For-Official-Use-Only]

Travis,

I tried to call earlier but missed you. I know you were speaking to s 22(1)(a)(ii) earlier today about some State and Territory data, and that she flagged that I'd be in touch with a complementary data request that Glenys and Caroline were talking about.

I know you are extremely busy, but wanted to put on your radar a few requests that came out of our meeting on Thursday that we'd be very keen to get from your team today:

- Request 1: I understand that today Health is updating the A3 grey scale pipeline document we discussed at our telecom on Thursday, along with additional info on s 22(1)(a)(ii) for Minister Hunt. Could that be provided to us when that is ready? Our Min is interested in the same info. We have a catch up with our Min at 530, so anything in advance of that appreciated, but understand if you end up working to a later deadline and happy to receive it ASAP after its provided to Min Hunt.
- Request 2: At our Thursday telecon we discussed that health was prioritising the contracts it would focus on to reflect that we were close to having sufficient stock for the NMS. Is it possible to indicate in the attached procurement report, which contracts are being prioritised for completion? Assume most of the 'other contracts under further development' and 'other contracts – screening' are not being prioritised except for s 22(1)(a)(ii) And that Health is prioritising the ones listed as 'expected for completion in next five days'? Also, would appreciate a heads up if there are any other and contracts completed over weekend and today that weren't picked up in your response to GB yesterday.

Also, as we get into a reporting swing, I wanted to put on your radar that the info we'd like to get from Health each day for our Min are as follows:

- **Contracts signed each day:** this should include info on where contract came from (Industry/health/other), what is included in contract (numbers to be delivered, when deliveries start and rough schedule) where the products coming from (Australia or another country)
- s 22(1)(a)(ii)

- **Barriers/intel/insights:** This is really for anything that Health sees that it would like our Minister to be aware of, e.g. when has enough been procured

Do you see any challenges in providing this? I've provided a similar list before, and understand s 22(1)(a)(ii) was looking into best way to meet these requests.

Thanks – as always, happy to discuss over the phone if any of this is extremely onerous to find a compromise that meets our Min's expectations without creating additional burden for Health.

W.

William Tan
A/g General Manager
Health Industry Coordination Group
Department of Industry, Science, Energy and Resources

s 22(1)(a)(ii), s 47F

E: s 22(1)(a)(ii), s 47F @industry.gov.au

From: s 22(1)(a)(ii), s 47F
To: s 22(1)(a)(ii), s 47F ; s 22(1)(a)(ii)
Cc: s 22(1)(a)(ii)
Subject: FW: FW: s 22(1)(a)(ii) Pty Ltd [DLM=For-Official-Use-Only]
Date: Tuesday, 7 April 2020 6:23:13 AM
Attachments: image001.gif
image002.gif

Hi All,
I am trying to get a time with Jo Mulder today to work through the triaging process but also case studies that they have - s 22(1)(a)(ii)

EY logo

s 22(1)(a)(ii), s 47F | s 22(1)(a)(ii), s 47F –
s 22(1)(a)(ii), s 47F

| s 22(1)(a)(ii), s 47F @au.ey.com

Mobile: s 22(1)(a)(ii), s 47F
Website: http://www.ey.com
EA: s 22(1)(a)(ii) @au.ey.com
s 22(1)(a)(ii)

From: s 22(1)(a)(ii)
Sent: Monday, April 6, 2020 6:59 AM
To: s 22(1)(a)(ii)
Cc: s 22(1)(a)(ii), s 47F
Subject: RE: FW: s 22(1)(a)(ii) Pty Ltd [DLM=For-Official-Use-Only]

s 22(1)(a)(ii) has been asked to lead this area (and specific need) and will be supported by s 22(1)(a)(ii), s 47F We have conversations going on with our China/ Asia Supplier Vetting teams already and are able to ramp up quite fast I believe.

s 22(1)(a)(ii), s 47F – please liaise with s 22(1)(a)(ii) et al to mobilise as fast and structured as possible.

Cheers - s 22(1

s 22(1)(a)(ii), s 47F
s 22(1)(a)(ii), s 47F

s 22(1)(a)(ii) @au.ey.com
Website: http://www.ey.com
s 22(1)(a)(ii) @au.ey.com

From: s 22(1)(a)(ii) @mckinsey.com>
Sent: Saturday, April 4, 2020 10:32 PM
To: s 22(1)(a)(ii) @au.ey.com>
Subject: Fwd: FW: s 22(1)(a)(ii) Pty Ltd [DLM=For-Official-Use-Only]

Hi s 22(1)(a)(ii)

See below. Not sure if possible for EY to help on this request for verification on such short notice. We've had some engagement with s 22(1)(a)(ii) already and happy to give a head up on this if you do want to look into it.

s 22(1)(a)(ii)

Sent from my iPhone

Begin forwarded message:

From: s 22(1)(a)(ii) @mckinsey.com>
Date: 4 April 2020 at 10:19:46 pm AEDT
To: "Beauchamp, Glenys" <s 22(1)(a)(ii), s 47F @industry.gov.au>
Subject: Re: [EXT]FW: s 22(1)(a)(ii) **Pty Ltd [DLM=For-Official-Use-Only]**

Hi Glenys
It seems the concern (understandably) is Supplier verification (is s 22(1)(a)(ii) connecting you with a reputable supplier, has someone vetted the factory etc). Unfortunately, McKinsey does NOT verify the supply chain. We don't have that capability.
Essentially, We've been helping triage and match make - We are provided with suggested suppliers by many referrers and sources (some of those do qualify vendors by calling them etc, some are just middle men), we obtain as much information as we can on them, we do an initial filter to remove those which are obviously fraudulent or with clearly invalid documentation. We then pass on the information to NSW or VIC. If they are interested to pursue we connect them to the source or supplier to discuss.
EY do have verification capabilities incl in China.
Our plan was to transfer the triaging / initial screen process to them and they would add on the vendor screening capability. A better solution for state and fed governments. That was going to happen early next week.
I will ask if they can help here, but am not sure how quickly they can mobilise. I can also ask s 22(1)(a)(ii)) if they have a screening partner if you like?
s 22(1)(a)(ii)

Sent from my iPhone

> On 4 Apr 2020, at 9:14 pm, s 22(1)(a)(ii) <s 22(1)(a)(ii) @mckinsey.com> wrote:
>
> Thanks GB
> I'll ask our team to look at this ASAP.
> s 22(1)(a
>
> Sent from my iPhone
>
> > On 4 Apr 2020, at 7:52 pm, Beauchamp, Glenys <s 22(1)(a)(ii), s 47F @industry.gov.au> wrote:
> >
> > Hi – if you can help unblock that would be great – don't know if we can wait till Monday, thanks, gb
> > Glenys Beauchamp
> > Health Industry Coordination Group
> > s 22(1)(a)(ii), s 47F
> >
> > For Official Use Only
> >
> > **From:** Mulder, Joanne
> > **Sent:** Saturday, 4 April 2020 6:52 PM
> > **To:** Purtell, Nick <s 47F @industry.gov.au>
> > **Cc:** McIntyre, Duncan

<s 22(1)(a)(ii), s 47F @industry.gov.au>; Beauchamp, Glenys <s 22(1)(a)(ii), s 47F @industry.gov.au>; <s 22(1)(a)(ii), s 47F @industry.gov.au>; Graham, Michele <s 22(1)(a)(ii), s 47F @industry.gov.au>; Health Industry Coord Group <HealthIndustryCoordGroup@industry.gov.au>; s 22(1)(a)(ii), s 47F @industry.gov.au>
Subject: RE: s 22(1)(a)(ii) Pty Ltd [DLM=For-Official-Use-Only]

Thanks Nick

I'm happy to ask McKinsey on Monday and clarify, and more than comfortable that EY will be involved.

I just wanted to make sure we understood the background and were following up in a timely way. If learn of anything in the meantime that would help us, please let me know.

Thanks for your help.

Jo

For Official Use Only

From: Purtell, Nick
Sent: Saturday, 4 April 2020 6:14 PM
To: Mulder, Joanne <s 22(1)(a)(ii), s 47F @industry.gov.au>
Cc: McIntyre, Duncan <s 22(1)(a)(ii), s 47F @industry.gov.au>; Beauchamp, Glenys <s 22(1)(a)(ii), s 47F @industry.gov.au>; @industry.gov.au>; Graham, Michele <s 22(1)(a)(ii), s 47F @industry.gov.au>; Health Industry Coord Group <HealthIndustryCoordGroup@industry.gov.au>; s 22(1)(a)(ii), s 47F @industry.gov.au>
Subject: Re: s 22(1)(a)(ii), s 47F Pty Ltd [DLM=For-Official-Use-Only]

For Official Use Only

Hi Jo

Thanks for checking in. I am very happy to ask McKinsey directly whether they have verified this supply chain (I'm talking to s 22(1)(a)(ii) a couple of times a day on other matters), but also happy for you to contact them directly as part of the work the department had contracted them to do. (I see you've set up a meeting with McKinsey on Monday - were you thinking of raising this then?

Based on the conversations I had with s 22(1)(a)(ii) I'm not aware that McKinsey had done any actual verification. I understood that the company had been contacted by McKinsey (not quite clear the context), and felt prepared to deal with any questions about supply chain.

Just FYI, I had understood that McKinsey was planning to use EY to do the supply chain

verification work that we've requested; so I'm not sure whether 'McKinsey' themselves will be doing any of the verification.
I think your current approach (s 22(1)(a)(ii) asking s 22(1)(a)(ii) for the necessary documentation) sounds like the right one. Would you like me to contact s 22(1)(a)(ii) and push this with him? I'm happy to.
Cheers
Nick

For Official Use Only

From: "Mulder, Joanne" <Js 22(1)(a)(ii), s 47F@industry.gov.au>
Date: Saturday, April 4, 2020 at 6:00:17 PM
To: "Purtell, Nick" <s 22(1)(a)(ii), s 47F@industry.gov.au>
Cc: "McIntyre, Duncan" s 22(1)(a)(ii), s 47F@industry.gov.au>, "Beauchamp, Glenys" <s 22(1)(a)(ii), s 47F@industry.gov.au>
Subject: FW: s 22(1)(a)(ii) Pty Ltd [DLM=For-Official-Use-Only]

Hi Nick
We were hoping you could clarify if McKinsey has verified the supply chain for this lead please? There is reference to McKinsey in the email trail.
We have also been engaging with s 22(1)(a)(ii) (see below) and asked for evidence that they are a certified supplier. They have not provided this information to us.
s 22(1)(a) from my team has emailed s 22(1)(a)(ii) again today and again requested documentation to show they are a certified supplier of the goods they are selling. As you know, we cannot recommend to the Dept of Health that they set up a contract without verifying the supply chain.
If you could clarify for us what's occurred, and if there are any next steps in train that we don't know about, that would be great.
Thanks
Jo

For Official Use Only
For Official Use Only

From: "Beauchamp, Glenys" <s 22(1)(a)(ii), s 47F@industry.gov.au>
Date: Saturday, 4 April 2020 at 12:38:31 pm
To: "McIntyre, Duncan" <s 22(1)(a)(ii), s 47F@industry.gov.au>
Cc: s 22(1)(a)(ii) @industry.gov.au>, "Health Industry Coord Group" <HealthIndustryCoordGroup@industry.gov.au>, "Graham, Michele" <s 22(1)(a)(ii), s 47F@industry.gov.au>, "Purtell, Nick"

<s 22(1)(a)(ii)@industry.gov.au>
Subject: FW: Ventilator novel supply lines - In Confidence [DLM=For-Official-Use-Only]

Hi all – s 22(1)(a)(ii) rang me today about this. I did not know where contract negotiations are up to and now just reading bottom of email train – thanks team. I did explain to s 22(1)(a that we need to be assured about TGA approved, they were physically there i.e. not in some production queue and freight/supply line 100% secure (I was told they were in a bonded warehouse?) and delivery in short term if it met all these requirements could be achieved. Assume our ventilator team will take this up, many thanks, gb

Glenys Beauchamp

Health Industry Coordination Group

s 22(1)(a)(ii), s 47F

For Official Use Only

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Subject: FW: Offer by s 22(1)(a)(ii) for consideration [DLM=For-Official-Use-Only]
Date: Friday, 17 April 2020 4:35:00 PM
Attachments: RE Ventilators SECUNCLASSIFIED.msg
RE Ventilators SECUNCLASSIFIED.msg
RE Ventilators SECUNCLASSIFIED.msg

---

s 22(1)(a)(ii)

Direct: s 22(1)(a)(ii) @au.ey.com

From: s 22(1)(a)(ii), s 47F
Sent: Friday, April 17, 2020 4:35 PM
To: s 22(1)(a)(ii)
Subject: FW: Offer by s 22(1)(a)(ii) for consideration [DLM=For-Official-Use-Only]

Hi guys, can you please send this off via the joint account?
s 22

s 22(1)(a)(ii), s 47F | s 22(1)(a)(ii), s 47F

Direct: +s 22(1)(a)(ii), s 47F @au.ey.com

s 22(1)(a)(ii)

Appendix B: Authorized Ventilators, Ventilator Tubing Connectors, and Ventilator Accessories
Updated: April 8, 2020

To be added to **Appendix B** (below), ventilators, ventilator tubing connectors, and ventilator accessories must be determined to meet the applicable conditions and criteria for safety, performance and labeling set forth in Section II, Section IV, and Appendix A. FDA will add a ventilator, ventilator tubing connector, and ventilator accessory to the list of authorized products in **Appendix B** (below) upon submission of a request from a sponsor as described in the Scope of Authorization Section of the Letter of Authorization (Section II) and pursuant to the Conditions of Authorization (Section IV) in this EUA and based on FDA's review and concurrence.

Ventilators

Manufacturer	Product Name	Device Description	Intended Use	Date of Authorization
Beijing Aeonmed Co., Ltd	VG70 ventilator	Critical Care Ventilator	Mechanical ventilation of patients in ICU	March 25, 2020

April 16, 2020 Our Ref. GX-RH-08

s 22(1)(a)(ii)

Dear s 22(1)(a)(ii)

FULL CORPORATE OFFER

For

Beijing AEONMED Model VG70 Ventilators

We are hereby to provide you our Full Corporate Offer for the procurement of BEIJING AEONMED Model VG70 Ventilators in China based on the detailed as follows:

我方在此依据下述具体的内容向贵司提供关于在华采购北京谊安 VG70 型号呼吸机的责任报价涵如下：

1	PRODUCT 产品	Model : VG 70 Ventilator 型号：VG70 呼吸机
2	Manufacturer 生产厂家	Beijing Aeonmed Co., Ltd. 北京谊安医疗系统股份有限公司
3	ORIGIN 原产国	China 中国
4	PACKAGING 包装	Suitable for long distance air transportation

From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Subject: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1 20200427.xlsx
Date: Monday, 27 April 2020 11:35:55 AM
Attachments: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1 20200427.xlsx

Instructions

ScreeningREF convention

s 22(1)(a)(ii)

Screening Dashboard

s 22(1)(a)(ii)

Primary Respondents List

Primary Respondent ID	Primary Respondent (entity) name	Business type	Business category	Products	DISER Case Number/s	Number of contracts	Total contract/s value (AU)*	Representative full name	Date created	Screening type	Screening progress	Risk asssessment	Primary reviewer

s 22(1)(a)(ii)

Supplier Screening Tracker

ScreeningREF	Date created	Primary Respondent ID	Primary Respondent (entity) name	Business type	Number of contracts	Total contract/s value (AU)	Representative full name	Screening type	Screening request sent date	Screening progress	Response received date	Review completed date	Reviewer	Overall risk assessment	Preliminary Observations/Rationale	Potential next steps	Other review comments
000101	16/04/2020	0001	s 22(1)(a)(ii)	Retailer	H073	$1	20477600	Initial Screen	10/04/2020	Review Complete	16/04/2020	23/04/2020	s 22(1)(a)(ii)	Medium risk	s 22(1)(a)(ii) warranty details require further clarity. Products are understood to be TGA approved plus plenty of information available online about the s 22(1)(a)(ii) s 22(1)(a)(ii) Some further details required for verification of information, such as warrantor details. Further information requested about the relationship with Aeonmed and its ability to provide service and support	Request further information on warrenty if DISER leads require additional ventilators	

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: s 47F
To: s 22(1)(a)(ii)
Subject: C19_Supplier Screening Tracker_v0.1.xlsx
Date: Monday, 20 April 2020 5:21:56 PM
Attachments: C19_Supplier Screening Tracker_v0.1.xlsx

Hi guys, it looks good, I've only edited 1-2 (in red). Key change is to be careful with our language. Everything should be "appears" (which you have done in some later ones).
With companies like s 22(1)(a)(ii) that get an ok rating, what are the types of questions we still have outstanding? What should the next steps be?

s 47F

Instructions

ScreeningREF convention

s 22(1)(a)(ii)

Primary Respondents List

Primary Respondent ID	Primary Respondent (entity) name	Representative full name	Date created	Screening stage	Screening step	Reviewer

s 22(1)(a)(ii)

Supplier Screening Tracker

ScreeningREF	Date created	Primary Respondent ID	Primary Respondent (entitv) name	Representative full name	Screening stage	Screening request sent date	Screening Step	Response received date	Reviewer	Overall risk assessment	Rationale	Recommended next step	Other review comments
000101	16/04/2020	0001	s 22(1)(a)(ii)		Initial Screen	10/04/2020	Review In Progress	16/04/2020	s 22(1)(a)(ii)	Medium risk	s 22(1)(a)(ii) and warranty details require further clarity. Products are understood to be TGA approved plus plenty of information available online about the s 22(1)(a)(ii) Some further details required for verification of information, such as warrantor details. Further information requested about the relationship wi h Aeonmed and its ability to provide service and	Request further information on warrantor	

s 22(1)(a)(ii)

From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Subject: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1) 20200427.xlsx
Date: Monday, 27 April 2020 3:22:39 PM
Attachments: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1) 20200427.xlsx

I have marked the updated columns in red

Instructions

s 22(1)(a)(ii)

OFFICIAL

Screening Dashboard

s 22(1)(a)(ii)

OFFICIAL

Primary Respondents List

Primary Respondent ID	Primary Respondent (entity) name	Business type	Business category	Products	DISER Case Number/s	Number of contracts	Total contract/s value (AU)*	Representative full name	Date created	Screening type	Screening progress	Risk asssessment	Primary reviewer
s 22(1)(a)(ii)													
s 22(1)(a)(ii)													

Supplier Screening Tracker

ScreeningREF	Date created	Primary Respondent ID	Primary Respondent (entity) name	Business type	Number of contracts	Total contract/s value (AU)	Representative full name	Screening type	Screening request sent date	Screening progress	Response received date	Review completed date	Reviewer	Overall risk assessment	Preliminary Observations/Rationale	Potential next steps	Other review comments
000101	16/04/2020	0001	s 22(1)(a)(ii)	Retailer	H073	$1	20477600	Initial Screen	10/04/2020	Review Complete	16/04/2020	23/04/2020	s 22(1)(a)(ii)	Medium risk	s 22(1)(a)(ii) warranty details require further clarity. Products are understood to be TGA approved plus plenty of information available online about the s 22(1)(a)(ii) s 22(1)(a)(ii) Some further details required for verification of information, such as warrantor details. Further information requested about the relationship with Aeonmed and its ability to provide service	Request further information on warrenty if DISER leads require additional ventilators	

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: s 47F
To: s 22(1)(a)(ii)
Cc: Mulder, Joanne; s 22(1)(a)(ii) s 47F ; s 22(1)(a)(ii)
Subject: C19_Supplier Screening Tracker and preliminary observations v1.0.xlsx
Date: Tuesday, 21 April 2020 4:59:14 PM
Attachments: C19_Supplier Screening Tracker and preliminary observations v1.0.xlsx

---

Hi s 22(1)(a) ,

Attached is the supplier screening tracker and our preliminary observations. It contains the status of all of the requests we've sent out and our preliminary observations. It would be good if you have time tomorrow to discuss further. Ideally we can discuss feedback and the need to obtain additional information from 1-2 suppiers.

It also contains a list of suppliers that DoH is understood to be negotiating with or has already contracted with. This will enable us collect standard information across the range of categories and suppliers.

s 47F

DOCUMENT 8A

Instructions

s 22(1)(a)(ii)

Primary Respondents List

Primary Respondent ID	Primary Respondent (entity) name	Representative full name	Date created	Screening type	Screening progress	Reviewer
s 22(1)(a)(ii)						
0014	s47G(1)		Unknown	21/04/2020	Supplier Information Form	Form to be issued	Unallocated
s 22(1)(a)(ii)						

Supplier Screening Tracker and Preliminary Observations

Draft and for discussion

ScreeningREF	Date created	Primary Respondent ID	Primary Respondent (entity) name	Representative full name	Screening type	Screening request sent date	Screening progress	Response received date	Reviewer	Overall risk assessment	Preliminary Observations/Rationale	Potential next steps	Other review comments
000101	16/04/2020	0001	s 22(1)(a)(ii)		Initial Screen	10/04/2020	Review In Progress	16/04/2020	s 22(1)(a)(ii)	Medium risk	s 22(1)(a)(ii) arranty details require further clarity. Products are understood to be TGA approved plus plenty of information available online about the s 22(1)(a)(ii) Some further details required for verification of information, such as warrantor details. Further information requested about the relationship with Aeonmed and its ability to provide service and support.	Request further information on warrenty if DISER leads require additional ventilators	
001402	21/04/2020	0014	s47G(1)		Unknown	Supplier Information Form	Form to be issued		Unallocated				

s 22(1)(a)(ii)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: s 22(1)(a)(ii)
To: s 22(1)(a)(ii)
Subject: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1).xlsx
Date: Wednesday, 22 April 2020 1:23:51 PM
Attachments: C19_Supplier Screening Tracker and preliminary observations v1.0 s 22(1)xlsx

Data in columns D to G

Instructions

s 22(1)(a)(ii)

s 22(1)(a)(ii)

Dashboard

s 22(1)(a)(ii)

Primary Respondents List

Primary Respondent ID	Primary Respondent (entity) name	Business type	DISER Case Number/s	Number of contracts	Total contract/s value (AU)	Representative full name	Date created	Screening type	Screening progress	Primary reviewer

s 22(1)(a)(ii)

Supplier Screening Tracker

ScreeningREF	Date created	Primary Respondent ID	Primary Respondent (entitv) name	Representative full name	Screening type	Screening request sent date	Screening progress	Response received date	Reviewer	Overall risk assessment	Preliminary Observations/Rationale	Potential next steps	Other review comments
000101	16/04/2020	0001	s 22(1)(a)(ii)	Authorised distributor	Initial Screen	10/04/2020	Review In Progress	16/04/2020	s 22(1)(a)(ii)	Medium risk	s 22(1)(a)(ii) warranty details require further clarity. Products are understood to be TGA approved plus plenty of information available online about the s 22(1)(a)(ii) s 22(1)(a)(ii) Some further details required for verification of information, such as warrantor details. Further information requested about the relationship with Aeonmed and its ability to provide service and support.	Request further information on warrenty if DISER leads require additional ventilators	

s 22(1)(a)(ii)

s 22(1)(a)(ii)